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Background: Recent scientific developments have shed more light on the importance of the host-microbe interaction,
particularly in the gut. However, the mechanistic study of the host-microbe interplay is complicated by the intrinsic
limitations in reaching the different areas of the gastrointestinal tract (GIT) in vivo. In this paper, we present the technical
validation of a new device - the Host-Microbiota Interaction (HMI) module - and the evidence that it can be used in
combination with a gut dynamic simulator to evaluate the effect of a specific treatment at the level of the luminal
microbial community and of the host surface colonization and signaling.
Results: The HMI module recreates conditions that are physiologically relevant for the GIT: i) a mucosal area to which
bacteria can adhere under relevant shear stress (3 dynes cm−2); ii) the bilateral transport of low molecular weight
metabolites (4 to 150 kDa) with permeation coefficients ranging from 2.4 × 10−6 to 7.1 × 10−9 cm sec−1; and iii)
microaerophilic conditions at the bottom of the growing biofilm (PmO2 = 2.5 × 10
−4 cm sec−1). In a long-term study,
the host’s cells in the HMI module were still viable after a 48-hour exposure to a complex microbial community. The
dominant mucus-associated microbiota differed from the luminal one and its composition was influenced by the
treatment with a dried product derived from yeast fermentation. The latter - with known anti-inflammatory properties -
induced a decrease of pro-inflammatory IL-8 production between 24 and 48 h.
Conclusions: The study of the in vivo functionality of adhering bacterial communities in the human GIT and of the
localized effect on the host is frequently hindered by the complexity of reaching particular areas of the GIT. The HMI
module offers the possibility of co-culturing a gut representative microbial community with enterocyte-like cells up to
48 h and may therefore contribute to the mechanistic understanding of host-microbiome interactions.
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The microbial community inhabiting the human gastro-
intestinal tract (GIT) can be seen as an additional organ
within the body able to produce key factors and bring
about specific metabolic pathways within the human
body [1-3]. Overall, the structure and composition of
this ecosystem reflects a natural selection at both micro-
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reproduction in any medium, provided the oraimed at functional stability [4]. This interaction mainly
occurs at the interface of the mucus and epithelial cell
barrier and may influence the regulation of host’s im-
mune and hormonal systems [5-8].
This close cross-talk is a complex area of study due to
the limited accessibility of the human GIT and the in-
trinsic limitations in recreating in vitro conditions rele-
vant for an in vivo-like interaction [9,10]. In the last two
decades, the need for systems that closely mimic the
in vivo situation led to the creation of dynamic in vitro
simulators in an attempt to reproduce the physiological
parameters of the GIT environment that influence theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Both the European Food Safety Authority (EFSA) and the
US Food and Drug Administration (FDA) support, as a
complementary tool, the use of the in vitro approach in
order to provide evidence of the mechanisms by which a
food/constituent could exert the claimed effect, and of the
biological plausibility of the specific claim (as reported in
the respective guidance). The most intensively used gut
simulators include the three-stage continuous culture
system, the SHIME® (Simulator of the Human Intestinal
Microbial Ecosystem), the EnteroMix, the Lacroix model
and the TIM-2 device [14]. Although these systems offer a
good reproducibility in terms of analysis of the luminal
microbial community [10,14,15], other aspects, such as
adhesion of bacteria and host-microbiota interaction are
not systematically addressed [16]. Adhesion can be evalu-
ated by means of cell immobilization in anaerobic
continuous-flow cultures [17,18]; by encasing mucin beads
within a dialysis membrane [19]; by introducing sterile
porcine mucin gels in small glass tubes [20] or on plastic
carriers (M-SHIME) [21] to determine how intestinal bac-
teria colonize and degrade mucus. The evaluation of the
host’s response is normally conducted by means of cell
culture experiments in plates [22], in a trans-well setup
[23], by the three-dimensional organotypic model of hu-
man colonic epithelium [24] or using the so-called human
gut-on-a-chip [25]. Independently of the used approach,
the combination of cell lines with complex microbial
communities (i.e. gut microbiota) is limited by the fact
that bacteria are highly cytotoxic for the cells, thus lim-
iting the experimental time to a few hours [10]. Finally,
none of the available devices offers the opportunity of
studying the gut biofilm formation and, at the same
time, the host-microbiota interaction under continuous
simulated conditions.
To overcome these limitations, we propose the use of
the Host Microbiota Interaction (HMI) module, taking
into account the particular characteristics of the host-
microbiota interface in the GIT. More specifically, the
aim was to establish a model that allows long-term
studies of a complex microbial community colonizing a
mucus layer, while being co-cultured - up to 48 h -
microaerophilically in the presence of shear forces and a
monolayer of enterocyte human cells. We first character-
ized a number of technical parameters of the HMI mod-
ule, and then we used the novel device together with the
SHIME® to evaluate the possibility of using the HMI
module for long-term studies of host-bacteria interac-
tions. The SHIME® consists of a succession of five reac-
tors simulating both the upper and the lower digestive
tract, with the first two reactors, mimicking the stomach
and small intestine, and the last three compartments
simulating physiological and microbiological parameters
representative of ascending, transverse and distal colon.We used, as a test compound, a dried product derived
from Saccharomyces cerevisiae’s fermentation that has
already been shown to have immune modulating/anti-
inflammatory properties both in vitro and in human
clinical trials [26-29]. We followed the effect of the treat-
ment on the composition of the luminal and mucosa-
associated microbial community and on the simulated
host’s response in terms of interleukin-8 production (a
pro-inflammatory cytokine produced by enterocytes in
response to bacterial triggers).
Results and discussion
The gut microbiome is an additional organ within our
body. To manage this complex community involved in
key functionalities for human health, it is important to
understand how bacteria interact with the host. This is
not always easy due to limited in vivo accessibility of the
GIT, particularly of the mucosal environment. In this study,
we introduced a new methodology to study the host-
microbe interaction under controlled in vitro conditions.
The HMI module
A new in vitro model, i.e. HMI module, was developed
to study the indirect host-microbe interaction in the
gastrointestinal tract. It comprises two parallel setups in
order to perform experiments in duplicate, with each
setup consisting of two compartments separated by a
functional double-layer (Figure 1). The upper compart-
ment simulates the luminal side of the GIT (with a
mixed microbiota from the SHIME), whereas the lower
compartment contains enterocytes, simulating the host.
Further, the functional double layer is composed of an
upper mucus layer and a lower semi-permeable poly-
amide membrane and has been conceived to potentially
serve multiple objectives: i) to provide a mucosal area
which can be colonized by the gut bacteria; ii) to allow
the bilateral transport of low molecular weight metabo-
lites; iii) to allow the transport of oxygen from the lower
to the upper side of the mucosal layer in order to create
microaerophilic conditions at the bottom of the growing
biofilm; and iv) to protect the host’s cells from direct ex-
posure to a complex microbial community and its toxic
effects. In this study the HMI module has been used in
i) short-term experiments to characterize different tech-
nical parameters and ii) in a long-term experiment,
coupled to a SHIME system (as described in the related
paragraph), to assess the possibility to follow up the
host’s response to a specific treatment up to 48 h.
Characterization of the technical parameters (shear stress,
mucus thickness and oxygen diffusion)
In the first part of the work the newly developed model
has been characterized with respect to a number of
technological parameters in order to validate it with
of cell medium
of bacterial suspension
Figure 1 Scheme of the HMI module for long-term studies of the host-microbiota interaction in the GIT. A polyamide semipermeable
membrane and a mucus layer form a double functional layer that separates the luminal compartment (upper one) from the lower compartment
containing enterocyte cell lines. The HMI module allows to study the bacterial adhesion under relevant shear forces and microaerophilic conditions. It
allows the reciprocal exchange of signals and metabolites between compartments and it allows the exposure of cell lines to a complex microbial
community, representative for the human colon, for up to 48 h.
Table 1 Permeability coefficients for metabolites and
oxygen (PmO2) in presence of a polyamide membrane
(pore size 0.2 μm) with and without mucus layer (200 μm)
(n = 2)
Polyamide membrane FITC dextran Oxygen
4 kDa 20 kDa 150 kDa
With mucus 2.4 ± 10−6 2.5 ± 10−7 7.1 ± 10−9 2.5 ± 10−4
Without mucus 5.6 ± 10−6 4.1 ± 10−7 6.5 ± 10−7 NDa
aND = not determined.
Data are expressed as cm sec−1. The permeation coefficient was lower in
presence of the mucus and with the increase of the FITC dextran kDa.
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been used as a separate unit (i.e. not coupled with a
SHIME).
The optimal shape of the HMI module was designed
to provide a homogeneous fluid shear distribution on
the surface of the mucus layer under different shear
forces relevant for the GIT (Additional file 1: Figure S1).
Analysis by Confocal Laser Scanning Microscopy (CLSM)
of the mucus layer on a vertical section and the evaluation
of the mucus thickness showed that 95% (i.e. residual
thickness) of the original mucus layer (200 μm) was still
present after 5 hours at medium shear stress (10 dynes/
cm2) and 45% after high shear stress (20 dynes/cm2) (data
not shown). Shear forces in the gut are a key factor in
shaping the adhering community, in affecting bacterial
gene expression and physiology, and can alternatively
favor or disfavor the adhesion of specific strains [30-32].
Physiological levels of shear stress found in the intestinal
epithelium during peristalsis may range between 35 and
0.02 dynes/cm2 [25,33,34]. We chose values below 5
dynes/cm2 as these are representative for the final part of
the ileum and beginning of the proximal colon. In fact, in
absence of microvilli, the fluid shear stress would vary
from about 1 to 5 dynes/cm2 [35].
Once the shape of the model and the flow were estab-
lished, we assessed the capacity of metabolites and oxy-
gen to permeate through the double functional layer of
the HMI module. A water solution containing FITC dex-
tran was flown in the upper compartment and samples
were collected from the lower compartment to measurethe fraction of fluorescent product that could permeate
through the double functional layer. The experiment
was conducted without and with a 200 μm mucus layer
on the membrane. The permeability coefficients ranged
from 2.4 × 10−6 cm sec−1 for the 4 kDa dextran to 7.1 ×
10−9 cm sec−1 for the 150 kDa dextran (Table 1), demon-
strating an inverse relationship between the size of the
metabolite and the degree of permeation. When compar-
ing modules with and without mucus layer, the presence
of mucus further induced a decrease in the permeability
of the test product (Table 1), as also shown by Desai et al.
[36]. The obtained values are in the same range of other
studies conducted with Caco-2 cells [25], perfused ani-
mals [37] or ex-vivo human colon tissues [38]. Behrens
et al. [39] reported that undifferentiated HT-29 cells
have a high permeability for 4 kDa dextrin (7 × 10−6
cm sec−1) which decreases with increasing thickness of
mucus to 1 × 10−6 cm sec−1. A similar setup was used to
Figure 2 MTT values (expressed as Optical Density – OD) of
Caco-2 cells directly exposed for 2 h to the complex microbial
community of the ascending colon of a SHIME reactor (direct
contact), exposed to the same microbial community within a
HMI module (HMI 1 and 2) or to sterile SHIME medium (control)
for 48 h. Values are averages ± standard deviation (n = 2).
* = statistically different from the control condition according to a
Student’s two-tailed t-test (p < 0.05).
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tional layer (mucus thickness of 200 μm). In this case O2-
saturated water (8.5 mg/L) was added in the lower
compartment while deoxygenized water was added in the
upper compartment. The oxygen concentration was then
measured in the upper compartment: an oxygen perme-
ability (PmO2) of 2.5 × 10
−4 cm sec−1 resulted in a diffu-
sion coefficient (DO2) of 5.0 × 10
−6 cm2 sec−1. The PmO2
value obtained with the HMI module was in line with the
ex vivo theoretical permeability diffusion calculated by
Saldena and colleagues [40] for a mucus layer of 115 μm
(i.e. PmO2 = 2.1 ⋅ 10
−4 cm sec−1).
Characterization of the biological parameters
A final set of short-term experiments was conducted to
assess the capability of bacteria to colonize the mucus
layer (200 μm) and to evaluate the survival of the enter-
ocytes in the lower compartment when exposed to a
complex microbiota.
In the first setup, a pure culture of Lactobacillus
rhamnosus GG (LGG) was flown in the upper compart-
ment. LGG was chosen as a positive control, because
human in vivo studies showed that the beneficial effects
of LGG are, in part, attributed to a strong colonization
of the colonic mucus layer upon oral administration
[41]. This strong adhesion capacity of LGG has recently
been attributed to a SpaC pilin, which is located on the
top of the pili and exerts a strong mucus-binding activity
[42]. After 1.5 h of incubation in the upper compartment
of the HMI module, LGG showed an adhesion percent-
age of 15.7 ± 3.2%, as compared to the original concen-
tration dosed to the model. This value is in line with
what described by Van den Abbeele et al. [21], who
tested the adhesive properties of LGG in presence of a
complex gut microbiota in a M-SHIME. The coloniza-
tion capacity of mucus by LGG was thus confirmed in
the HMI module.
Finally, the HMI module containing enterocytes in the
lower compartment was challenged for the first time
with a complex microbiota originated from the simu-
lated ascending colon of the SHIME. In parallel the
enterocytes were also directly exposed to the same com-
plex microbiota. A MTT test showed that the viability of
Caco-2 cells directly exposed to the complex microbial
community decreased by 80% after 2 hours of co-
culture. In contrast, when the interaction occurred
within an HMI module, the cells’ viability after 48 h of
incubation was not significantly different as compared to
a control system in which only sterile SHIME medium
was dosed (Figure 2). Although the use of cell cultures,
such as Caco-2 cells, is not novel for mechanistic studies
[29,43,44], the output of these reductionist studies is
limited by the fact that they are normally conducted
using pure bacterial cultures, a mix of few bacterialstrains or filtered growth media. This is mainly related
to the fact that mixed microbial slurries are too cyto-
toxic (Figure 2), thus limiting the experimental time (a
few hours at most) and the adaptation of the host to the
microbial metabolism. On the contrary, the HMI mod-
ule allows to indirectly expose the Caco-2 cells to the
gut microbiota for up to 48 h, the average in vivo expos-
ure time of an enterocyte to the content of the gut
lumen when migrating from the crypts to the top of the
villi [45].
Long-term experiment
After the validation of the technical/biological parame-
ters in independent experiments, the HMI module was
used in combination with an adapted SHIME (Figure 3)
to test the effect of a dried, modified Saccharomyces cer-
evisiae fermentation product (EpiCor®, Embria Health
Sciences, USA). The adapted SHIME consisted of a suc-
cession of three reactors: the first two reactors are of the
fill-and-draw principle to simulate different steps in food
uptake and digestion by simulating, respectively, stom-
ach and small intestine; the last compartment, simulat-
ing the ascending colon (AC), was a continuously stirred
reactor with constant volume, pH control and inoculation
with fecal microbiota. As described in more detail in the
‘Methods’ section, two HMI modules were connected to
the AC vessel of the SHIME during the last three days of
the control and of the treatment week (Figures 3 and 4).
Considering the average of three sampling points in
the SHIME experiment (Figure 4), the treatment with
the dried-fermented yeast product induced a 35% in-
crease in total short chain fatty acids (SCFA) production
in the lumen of the simulated AC (from 73.6 ± 1.4 to
99.7 ± 3.5 mmol/L) with a 41% increase of acetate (from
AC
N2
Stomach Small intestine Ascending Colon
pH = 5,6 – 5,9 
V = 500 mL
Res. time = 20h
Air connections
pH controller
SHIME feed
Pancreatic juice
Bile salts
Liquid connection SHIME bacteria
pH electrode
Pump
HMI modules
Cell medium
Sample collection
Liquid connection HMI cells
Figure 3 Scheme of the adapted SHIME system (consisting of stomach, small intestine and ascending colon - AC - compartments) used
for the long-term study. Two HMI modules have been connected in parallel to the vessel simulating the AC compartment in order to obtain
information on bacterial adhesion and host response after 24 and 48 h. The SHIME system was fed three times per day with SHIME feed; the
medium in the lower compartment of the HMI modules (containing Caco-2 cells) was fully replaced every 6 hours by means of an automatic
pump. The exhausted medium was collected in order to analyze the concentration of IL-8.
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onate (from 17.0 ± 1.0 to 18.1 ± 1.1 mmol/L) and a 31%
increase of butyrate (from 13.6 ± 0.5 to 17.8 ± 0.6 mmol/L)
(p < 0.05).
Quantitative PCR data at luminal level in the AC
showed that at the moment of connecting the HMI
module to the SHIME during the treatment period, the
concentration of all the analysed microbial groups was
lower as compared to the respective time point during
the control period. Despite this, at the end of the 48 h-
treatment period, the bacteria concentration of all groups
were equal or higher than the respective sampling pointsCStart up
2 wks
SCF
DNA
Sa
m
pl
es
 c
ol
le
ct
io
n
IL8
DNA
SHIME
HMI
Figure 4 Scheme of the long-term experiment and of the relative sam
of a 2-week startup period, 1-week control and 1-week treatment. The HM
SHIME system during the last 3 days of the control and treatment periods.
DNA analyses. Samples from the surface of the double functional layer of t
lower compartment of the HMI module were collected for IL-8 measureme
only at 48 h).during the control period (Table 2). At mucosal level, all
microbial groups at the end of the treatment showed a
lower concentration with the exception of the Lactobacil-
lus spp. which, at 48 h, was 2 log higher as compared to
the same time point during the control period.
The cluster analysis based on a composite data set of
the DGGE gels for total bacteria (Additional file 1:
Figure S2), bifidobacteria (Figure 5a) and lactobacilli
(Figure 5b) is shown in Figure 5c. The samples from
control and treatment period clustered separately (clus-
ter I and II). Moreover, within each cluster, luminal sam-
ples and mucosal samples sub-clustered in two differentontrol Treatment
1 wk 1 wk
EpiCor addition
0 24 48 0 24 48
A SCFA
DNA
IL8
DNA*
X
X X X
X X
X X
X X X
X X
X X
XX X X X
pling points for the different analyses. The experiment consisted
I modules were connected to the ascending colon compartment of a
Samples from the lumen of the SHIME were collected for SCFA and
he HMI modules were collected for DNA analyses. Samples from the
nts. DNA = qPCR and DGGE. DNA* = qPCR, DGGE and FISH (the latter
Table 2 Bacterial concentration of different microbial groups quantified by specific qPCR in luminal (L) (n = 3) and mucosal (M) (n = 6) samples of the HMI module
during control and treatment at time 0, 24 and 48 h
Control (A) Treatment (B)
0 h 24 h 48 h 0 h 24 h 48 h
L L M L M L L M L M
Total Bacteria Avg. 2.46 × 1010 1.31 × 1010 5.71 × 108 9.08 × 109 6.35 × 108 6.35 × 109 6.27 × 109 2.43 × 108 7.79 × 109 2.31 × 107
Std. Dev. 1.12 × 109 1.53 × 108 2.83 × 108 4.77 × 108 8.44 × 108 3.14 × 108 7.54 × 107 1.75 × 108 2.29 × 108 2.56 × 106
Bacteroidetes Avg. 7.60 × 109 6.29 × 109 5.25 × 108 4.58 × 109 2.78 × 108 1.41 × 109 4.50 × 109 9.82 × 107 1.13 × 1010 6.59 × 107
Std. Dev. 1.23 × 109 2.77 × 109 3.60 × 108 1.20 × 109 3.65 × 108 1.83 × 108 6.96 × 108 6.07 × 107 1.79 × 109 3.44 × 107
Firmicutes Avg. 1.65 × 109 1.64 × 108 2.08 × 107 2.85 × 108 1.67 × 107 7.88 × 108 4.29 × 108 3.65 × 106 5.43 × 108 9.65 × 105
Std. Dev. 2.79 × 108 1.02 × 107 3.80 × 106 2.52 × 107 3.20 × 106 7.21 × 107 3.96 × 107 1.60 × 106 4.11 × 107 7.41 × 105
Bifidobacteria Avg. 9.39 × 108 2.73 × 108 3.35 × 108 3.24 × 108 8.49 × 106 1.26 × 108 3.79 × 108 1.25 × 106 4.43 × 108 3.37 × 105
Std. Dev. 1.23 × 108 2.65 × 107 5.09 × 107 2.97 × 107 9.80 × 105 2.89 × 107 1.40 × 108 1.38 × 105 2.44 × 107 1.74 × 105
Lactobacilli Avg. 1.88 × 107 3.86 × 106 1.30 × 105 6.81 × 105 3.45 × 102 8.06 × 105 1.77 × 105 1.45 × 103 1.37 × 106 5.85 × 104
Std. Dev. 3.47 × 106 3.45 × 105 7.75 × 104 5.40 × 105 3.89 × 102 1.69 × 105 1.54 × 105 1.67 × 103 2.52 × 105 7.86 × 104
Data for L are expressed as 16S rRNA gene copies/mL of SHIME suspension; those for M correspond to 16S rRNA gene copies cm−2 of simulated gut wall. Values in bold indicate samples from the treatment period
which are significantly higher than the control at the same sampling time, according to a Student’s two-tailed t test (p < 0.05). Values in italics are significantly lower.
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Figure 5 DGGE fingerprinting analysis for bifidobacteria (a) lactobacilli (b) and composite data set of the gels for bifidobacteria.
lactobacilli and total bacteria, including bootstrap analysis with 1000 samplings (c). A = control period (Cluster II); B = treatment period (Cluster I).
L = luminal samples collected from the SHIME reactor; M =mucus sample collected from a fraction of the membrane inside the HMI module. 0,
24 and 48 indicate the hours that the HMI modules have been connected to the SHIME system during the control and treatment periods (as
illustrated in Figure 3). Clustering analysis was based on the Pearson product–moment correlation coefficient and dendrograms were created by
using UPGMA linkage.
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http://www.biomedcentral.com/1471-2180/14/133groups (Figure 5c). The DGGE specific for bifidobacteria
(Figure 5a) showed that two distinct Bifidobacterium
spp. – indicated by an arrow and a black square could
benefit from the treatment and specifically colonize the
mucus layer. The Bifidobacterium sp. identified by the
black square was only dominant in the microbial biofilm
during the week of treatment. Also for lactobacilli, the
DGGE showed qualitative changes due to the treatment
(Figure 5b). The Lactobacillus sp. indicated by the black
arrow, initially present both in the luminal and the
mucosal microbial community, were lost during the
treatment. On the contrary, the treatment selectively en-
hanced those species within the dashed square, species
that preferentially adhere to the simulated gut surface.
These molecular data showed that by means of an HMI
module connected to the SHIME, it was possible to
evaluate the modulating effect of the test product both
on the luminal and mucosa-associated microbiota. The
latter was different from the luminal one (in terms of
relative abundance of the main species) as the mucin
layer is colonized by a biofilm with bacterial species that
specifically (i) adhere to mucins, (ii) metabolize mucins
or (iii) proliferate in mucus due to the microaerophilic
conditions at the bottom of this layer. This is also the
case in vivo, where it was shown for instance that theM
O
a)
b)
20 µ
Figure 6 FISH analyses a) positioning of F. prausnitzii (left panel - fluo
Laser Scanning Microscopy) in the microbial biofilm with respect to t
arrows. Oxygen concentration (O2) is assumed to decrease from the bottom
the matrix: EPS, and non-responding bacteria in the left panel, while in the rig
labeled, and also some auto-fluorescent EPS. b) Concentration of F. prausnitzi
mucus layer (M) of the HMI module during the treatment period determinedmucosa-associated microbiota differs from the dominant
fecal microbiota in both healthy subjects and patients
with IBD [46].
Finally, the positioning of two specific microbial
groups (i.e. bifidobacteria and Faecalibacterium praus-
nitzii) in the mucus layer as analysed by FISH, provided
an additional proof of the validity of the HMI module as
compared to the in vivo situation (Figure 6). While the
strict anaerobic bifidobacteria tended to colonize the
upper side of the mucus layer, F. prausnitzii mainly oc-
curred in the lower part of the mucus, i.e. at the anoxic/
oxic interphase (Figure 6a). Khan et al. demonstrated
that F. prausnitzii can grow in the oxic-anoxic inter-
phase due to the fact that this microorganism, despite
being oxygen sensitive, copes with O2 because of a spe-
cial extracellular electron shuttle of flavins and thiols
[47]. Similar to the in vivo situation - where small
amounts of oxygen permeate from blood vessels towards
the gut lumen - in the HMI module, oxygen diffusion
from the aerobic lower chamber to the anaerobic upper
chamber (Figure 1) probably results in microaerophilic
conditions at the base of the biofilm, allowing for F.
prausnitzii to specifically colonize this niche. The qPCR
data showed a decreasing concentration of F. prausnitzii
in the luminal compartment and an increasing one in2
Luminal F.p.
Mucosal F.p.
Luminal Bif.
Mucosal Bif.
20 µ
rescent microscopy) and bifidobacteria (right panel - Confocal
he membrane and mucus layer (M), as indicated by the white
to the top of the biofilm. The green background is auto-fluorescence of
ht panel it corresponds to bacteria stained with the EUB338 probe FITC
i (F.p.) and Bifidobacterium spp. (Bif.) in the lumen of the SHIME (L) and
by specific qPCR (n = 3).
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The concentration of bifidobacteria remained unaffected
in the luminal part while tended to decrease in the
mucus layer compartment. The FISH data thus demon-
strate the potency of the HMI module to preserve the
regional colonization of specific gut microorganisms
within the mucus layer.
Finally, the possibility of exposing the enterocytes to
complex microbial communities for a prolonged period
allowed us to follow up the response of the host-like
cells to the specific treatment. Figure 7b shows that,
after 24 h and 48 h, the morphology of the Caco-2 cells
during and at the end of the treatment period was com-
parable with that of the cells at the beginning of the ex-
periment. Moreover, the cells remained attached as a
monolayer to the collagen substrate and were viable (no
statistically significant difference in terms of MTT
values). The samples collected from the lower chamber
when the medium was replaced every 6 h (‘6 h-sample’)
were used to assess the residual concentration of O2 and
the production of IL-8 by Caco-2 cells. The dissolved O2
in the fresh cell medium was 8.44 mg L−1. This concen-
tration decreased to 7.75 ± 0.06 mg L−1 in the ‘6 h-sam-
ple’ at 6 h, to 7.25 ± 0.06 mg L−1 in the ‘6 h-sample’ at
24 h and to 7.22 ± 0.03 mg L−1 in the ‘6 h-sample’ at
48 h. This indicates that the O2 concentrations did not
decrease dramatically in the lower compartment over
time. The treatment with the yeast fermentate resulted
in an anti-inflammatory response as evidenced by0 h 24 h
a
b
Figure 7 Cytokine production and enterocytes (a) data related to the
as (pg mL−1)/h; the standard deviation was calculated on the readings of t
from the HMI modules of the SHIME treated with the test product to evalusignificant lower IL-8 production after 48 h (p < 0.05), as
compared to the control (Figure 7a). The significant de-
crease in pro-inflammatory IL-8 production has already
been correlated with a SCFA profile that shifted towards
an increased production of butyrate [29].
Conclusions
The study of the in vivo functionality of adhering bacter-
ial communities in the human GIT and of the localized
effect on the host is frequently hindered by the complex-
ity of reaching particular areas of the GIT, and by the
lack of suitable in vitro models simulating the actual
GIT complexity. In order to overcome this limitation we
proposed the HMI module as a simplified simulation of
the processes occurring at the level of the gut wall (i.e.
shear stress, O2 and metabolites permeation, bacterial
adhesion and host response). Three unique advantages
can be ascribed to this new device, as compared to other
systems available for research purposes: i) the possibility
to simulate at once the bacterial adhesion to the gut wall
and the indirect effect on human cell lines; ii) the possi-
bility of performing these studies up to 48 h with a com-
plex microbiota, representative of that inhabiting the
human gut; iii) the possibility to couple the HMI module
to a continuous simulator of the human gastrointestinal
tract (i.e. SHIME). The latter is of key importance when
analyzing the effect of specific products, as for instance
prebiotic fibers. In fact, the health-modulating effect of
fibers is often related to the metabolites produced by48 h
IL-8 production along the experiment (n = 2). Data are expressed
he two parallel setups. (b) Microscopy scans of the cell lines collected
ate the morphology at time 0, 24 and 48 h.
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http://www.biomedcentral.com/1471-2180/14/133microbial species by means of cross-feeding [48,49]. For
instance, primary users often degrade part of an ingredi-
ent to smaller fragments, sugar monomers, and SCFA
such as acetate or lactate. The latter two are precursors
for the production of the anti-inflammatory SCFA butyr-
ate by other species [50]. The efficiency of this mechan-
ism is frequently related to the adaptation of the
microbial metabolic functionalities to the fiber and, in
order to exert this effect, repeated doses of the ingredi-
ent are needed [29]. This is exactly what the combin-
ation ‘SHIME-HMI module’ allows to study: repeated
doses of a product are provided to the microbiota of the
SHIME; the product modifies the composition and activ-
ity of the luminal and mucosal microbiota and, ultim-
ately, this modulates the host’s response.
Several opportunities lay in the future to improve
the host compartment of the HMI module. Among
them, the most challenging would be the incorporation
of co-cultures of enterocytes and immune cells or of
three-dimensional organotypic model of human co-
lonic epithelium [24].
Methods
The HMI module
The HMI module consists of 2 compartments (each meas-
uring 10 × 6 cm) separated by a functional double-layer
composed of an upper mucus layer and a lower semi-
permeable membrane (Figure 1). The upper compartment
represents the luminal side of the GIT, whereas the lower
compartment contains enterocytes representing the host.
The polyamide membrane has a pore size of 0.2 μm and
a thickness of 115 μm (Sartorius Stedim, Vilvoorde,
Belgium). The mucus layer was prepared by boiling
autoclaved distilled H2O containing 5% porcine mucin
type II (Sigma Aldrich, St. Louis, MO, USA) and 0.8%
agar. The pH was adjusted to 6.8 with 10 M NaOH. A
mucus layer ranging between 200 and 250 μm (depending
on the experiment) [51] was poured onto a wet membrane
by means of an Elcometer 4340 Motorised/Automatic Film
Applicator (Elcometer SA, Hermalle/s Argenteau, Belgium).
Caco-2 cells (ATCC HTB37) were cultivated in
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with Glutamax (Gibco), 10% fetal bovine serum
(Greiner Bio-One, Wemmel, Belgium), 1% non-essential
amino acids and 2% penicillin/streptomycin + 2.8 μg/ml
amphotericine B (fungizone) at 5% CO2 in air. Before the
experiment, 88.000 cells/cm2 were seeded on glass slides
covered overnight with rat-tail collagen of type I (BD Bio-
sciences, Belgium) and grew till confluence [52]. After
7 days of culture, the cells were ready to be challenged
with bacteria. During the experiments, the cells were
maintained in the same medium but without antibiotics
and antimycotics to avoid killing the bacteria growing in
the upper chamber.Characterization of the technical parameters
Hydrodynamics studies (computational fluid dynamics)
were carried out by means of Fluid 6.0 CFD software
(ANSYS, Canonsburg, USA) [53]. The aim was to evalu-
ate the best design for generating a homogeneous flow
within the compartments under different shear forces
representative of the upper and distal small intestine and
of the colon (i.e. 25, 12 and 2 dynes cm−2, respectively).
The adhesive capacity of the mucus layer to the poly-
amide membrane was evaluated by means of CLSM.
Two HMI modules were set up and fluorescein isothio-
cyanate (FITC) dextran (4 KDa), a fluorescent com-
pound, was added to the mucin/agar layer in order to
make the mucus visible by CLSM. The integrity of the
mucus layer (200 μm) was analyzed after a 5-hour incu-
bation period under either medium or high shear stress
(i.e. 10 and 20 dynes/cm2). Data were calculated as per-
centage of residual mucus (after 5 h) on the membrane
as compared to Time 0, analyzing a vertical section of
the functional double layer.
In a separate experiment, three HMI modules were set
up to evaluate the permeation of metabolites of different
dimensions and molecular radius through the double
functional layer by means of a water solution containing
FITC conjugated dextran of 4, 20 and 150 kDa, as model
compounds. The permeability of the polyamide mem-
brane was assessed with and without a 200 μm mucus
layer and at a constant flow of 6.5 mL min−1. A standard
curve based on the molar concentration was created for
each compound. Measurement of the fluorescent com-
pounds (collected from the lower compartment) at an
excitation wavelength of 485 nm and an emission wave-
length of 530 nm and calculation of the permeability co-
efficient (Pc) was conducted as reported in Ambati et al.
[54], using the following equation:
Pc ¼ C3:5−C0:5ð Þ  V
A t  C0
where C3.5 and C0.5 were the concentration of the FITC
dextran in the lower compartment at 3.5 h and 0.5 h, re-
spectively, V the volume of the compartment, A the area
of the membrane, t the time of the experiment and C0
the initial concentration of FITC dextran in the upper
compartment.
The oxygen permeability was measured in a HMI
module (with a mucus layer of 200 μm) maintaining a
completely anaerobic upper chamber (water previously
gassed with 95% N2-5% CO2) and an aerobic lower cham-
ber (liquid constantly gassed with an air pump). Mea-
surements were carried out at 37°C by following the
increasing oxygen concentration in the upper chamber by
means of a luminescent LDO oxygen probe (Hach Lange,
Mechelen, Belgium) placed on the outlet connection of
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oxygen concentration in the upper chamber, collected in
the first 30 minutes, were used to calculate the relative
permeability (PmO2) using the following equation, as
shown by Saldena et al. [40]:
MO2 ¼ DO2 S  t  cO2ð ÞA− cO2ð ÞB
x
where MO2 is the mass of oxygen transferred in the time
t; (cO2)A and (cO2)B are the concentrations of oxygen in
the upper and lower chamber of the HMI module with a
mucus layer with a surface S and a thickness x. The quo-
tient DO2/x corresponds to the oxygen permeability
(PmO2).
Characterization of the biological parameters
Lactobacillus rhamnosus GG (LMG 18243, BCCM/
LMG, Ghent, Belgium) was used as a positive control to
assess the capacity of bacteria to colonize the double
functional layer [55]. LGG was grown in MRS medium,
quantified by plate count (LGG t0). The fully grown li-
quid culture was then circulated through the upper
chamber of an HMI module at a flow correspondent to
a shear stress of 3 dynes cm−2 (6.5 mL min−1). After
1.5 h, the simulation was stopped and the luminal sus-
pension removed. The functional layer was rinsed twice
with phosphate buffer solution to remove the non-
adhered bacteria. Subsequently, the luminal side of the
functional layer was rinsed with Triton X-100 to remove
the adhering bacteria. The obtained bacterial suspension
was analyzed for microbial concentration measurements
using the plate count technique on MRS (LGG t1.5).
Percent of adhering bacteria was calculated as LGG t1.5/
LGG t0.
In a second set of experiments, it was evaluated the
capacity of Caco-2 cells to survive in the HMI module
in presence of a complex microbial community (derived
from a SHIME reactor). An HMI module was set up as
described in the first paragraph of the Methods section
and the complex microbial community was introduced
in the upper chamber of the HMI module. In a parallel
experiment, the enterocytes were directly exposed to the
same microbiota (i.e. viability after direct contact) in a
microtiter plate. The cell viability in the 2 setups was
compared by means of the MTT ((3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) colorimetric test
[56] after 48 h of incubation in the HMI module and after
2 h of direct contact.
SHIME experiment
The HMI module was used in combination with an
adapted Simulator of the Human Intestinal Microbial
Ecosystem (SHIME®) to test the effect of a dried,modified Saccharomyces cerevisiae fermentation product
(EpiCor®, Embria Health Sciences, Ankeny, Iowa, USA).
S. cerevisiae is anaerobically fermented in a proprietary
medium and the whole medium is dried to inactivate the
yeast and then ground to a suitable particle size leading
to the following composition for 100 gram of product:
carbohydrates 39%, total dietary fiber 11.9%, protein
27.9%, total fat 2.07%, and cholesterol 0.02%. The
adapted SHIME consisted of a succession of three reac-
tors [57,58] (Figure 3). The first two reactors are of the
fill-and-draw principle to simulate different steps in food
uptake and digestion, with peristaltic pumps adding a
defined amount of a carbohydrate-based nutritional
medium (140 mL 3 time/day) and pancreatic and bile li-
quid (60 mL 3 times/day), respectively to the stomach
and duodenum compartment and emptying the respect-
ive reactors after specified intervals. The last compart-
ment is a continuously stirred reactor with constant
volume and pH control. Upon inoculation with fecal
microbiota and a proper adaptation time of 2 weeks to
ascending colon (AC) conditions, this reactor harbors a
community that resemble that present in the AC [11,59].
Inoculum preparation, retention time, pH, and tem-
perature settings were previously described [58]. The
nutritional medium was composed as follows: arabinoga-
lactan (1 g L−1), pectin (2 g L−1), xylan (1 g L−1), starch
(5 g L−1), glucose (0.4 g L−1), yeast extract (3 g L−1), pep-
tone (1 g L−1), mucin (4 g L−1), cysteine (0.5 g L−1). The
fecal sample to start this SHIME experiment was derived
from a healthy individual, who had no history of anti-
biotic treatment in the last year. The ethical approval to
use human fecal samples to perform in vitro studies was
granted by the Commission for Medical Ethics of UZ
Gent (registration number B670201214538). After the
reactor start up, the system was allowed to stabilize for
2 weeks before the start of the experiment [59]. The
long-term experiment consisted of a 1-week control
period in which the standard nutritional medium was
administered to the model (condition A). After this, a
treatment period of 1 week was performed in which the
nutritional medium was supplemented with 4 g L−1 of
yeast fermentate (condition B). To compensate for the
additional administration of carbon sources, a corre-
sponding amount of starch was removed. Two HMI
modules, with a mucus layer of 250 μm, were connected
to the AC vessel of the SHIME during the last three days
of the control and of the treatment week. A constant
flow of 6.5 mL min−1 (=3 dynes cm−2) of luminal sus-
pension from/to the AC - by means of an 8-channel
pump-head - (Figure 3) was maintained in the upper
compartment. The medium in the lower compartment
containing the enterocytes was replaced every 6 h by
means of automatic pumping (8-channel pump-head), at
a flow of 2 mL min−1. The exhausted medium was then
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HMI module to analyze the response of Caco-2 cells to
the treatment in terms of production of inflammatory
cytokines. For this purpose the samples were frozen at
−20°C. The same samples collected at 6 (n = 4), 24 (n = 4)
and 48 h (n = 2) were first used to measure the residual
O2 concentration by means of a LDO probe. The HMI
modules were maintained at a temperature of 37°C by
means of a portable incubator (JP Selecta, Abrera, Spain).
To analyze the effect of the yeast fermentate on the
microbial community composition, liquid samples were
collected from the AC reactor during the control and
treatment period (Figure 4). After 24 h and 48 h of incu-
bation, a sterile blade was used to cut 6 cm2 of the
membrane and mucus layer in the HMI module to col-
lect samples to analyze the adhering bacteria. Samples
were named as follows: A or B (control or treatment) +
L or M (luminal or mucus compartment) + 0, 24 or 48
(time of incubation). Figure 4 shows a timeline of the ex-
periment with relative sampling points.
Biochemical and molecular analyses
SCFA and ammonium production: the microbial com-
munity activity in the AC was measured in terms of
short-chain fatty acid (SCFA) and ammonium produc-
tion as described by Van de Wiele et al. [60].
Denaturing Gradient Gel Electrophoresis (DGGE): the
structure and composition of the microbial community
was evaluated using DGGE on total bacteria, bifidobac-
teria and lactobacilli [60]. Metagenomic DNA was ex-
tracted from the L and M samples as previously
described [61]. DGGE with a 45–60% denaturing gradi-
ent (50-65% for bifidobacteria) was used to separate the
polymerase chain reaction (PCR) products obtained with
a nested approach for the 16S rRNA genes of bifido-
bacteria (primers BIF164f-BIF662r) and lactobacilli
(SGLAB0159f-SGLAB0667r). The first PCR round was
followed by a second amplification with primers 338 F-
GC and 518R. The latter primers were also used to amp-
lify the 16S rRNA gene of all bacteria on total extracted
DNA. The DGGE patterns obtained were subsequently
analyzed using the Bionumerics software version 5.10
(Applied Maths, Sint-Martens-Latem, Belgium). In brief,
the calculation of similarities was based on the Pearson
(product–moment) correlation coefficient. Clustering
analysis was performed using the unweighted pair group
method with arithmetic mean clustering algorithm
(UPGMA) to calculate the dendrograms of each DGGE
gel. A cluster analysis was also performed on a compos-
ite dataset of all the gels with band-matching, Pearson
correlation with standardized characters and bootstrap
analysis with 1000 samplings.
Quantitative PCR (qPCR): Quantitative polymerase
chain reaction (qPCR) for total bacteria, bifidobacteria,and lactobacilli were performed as reported by Posse-
miers et al. [62]. The qPCR for the Firmicutes and Bac-
teroidetes phyla was previously described by Guo et al.
[63]; that for Faecalibacterium prausnitzii by Vermeiren
et al. [64].
Fluorescent in situ hybridization (FISH): 0.5 cm2 of the
membrane were fixed in a solution containing 4% para-
formaldehyde in phosphate buffered saline (pH7.2) and
ethanol (1:1) at room temperature for 24 hrs and kept at
4°C for 5 days. The fixed membranes were subsequently
embedded into paraffin wax blocks using standard la-
boratory techniques. Sections of 4 μm-thickness were
cut off the paraffin blocks and were placed on StarFrost®
slides (Waldemar Knittel Glasbearbeitungs- GmbH,
Germany). To localize different groups of major intes-
tinal bacterial, the obtained slides were hybridized with
probes Bif164 for bifidobacteria and Fprau0645 for Fae-
calibacterium prausnitzii as described in Harmsen et al.
[65]. To visualize all the bacteria, the hybridizations were
combined with the universal Eub338 probe, labeled with
either rhodamine or FITC to contrast the labels of the
group-specific probes. These slides were visualized using
a Leica Epi-fluorescence microscope (Leica, Germany)
and a Zeiss, LSM 780 Confocal laser scanning micros-
copy (CLSM) (Zeiss Jena, Germany). The obtained pic-
tures were evaluated using ImageJ software.
Cytokines detection: the supernatants from the cells
compartments were assayed for the presence of interleu-
kins IL-8 by using a commercially available ELISA kit
and according to the manufacturer’s instruction (Quanti-
kine ELISA, R&D Systems, Minneapolis, USA). Statisti-
cally significant differences of the treatment period, as
compared to the average of the control period, were
evaluated with a Student’s two-tailed t-test. Differences
were considered significant if p ≤ 0.05.Additional file
Additional file 1: Figure S1. Computational fluid dynamics simulation
of the module chamber under different shear forces. Figure S2. Clustering
of DGGE fingerprinting analysis for total bacteria.Competing interests
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